Silvia Cainarca presented data obtained in WP3, WP5 and WP6.
Treatment of Neuropathic pain (NP) still constitutes an unmet need, with a high-multidimensional impact on society. Multiple causes of NP have been described and, among these, the activation of glial cells and neuro–glial interactions represent key mechanisms.
The aim of our IMI granted project, in partnership with academia (KCL, NMI), pharmaceutical industries (Esteve, Grünenthal) and biotech companies (Axxam, LIFE&BRAIN) is to in vitro recapitulate the in vivo mechanisms of chronic NP focusing on the development of hiPSC-derived neuron-glia co-culture system.
Here, we describe the generation of novel reporter systems for in vitro modelling of pain through genome editing of iPSCs, and the setup of high content/high throughput screening assay platforms for the identification of novel therapeutic molecules based on NP-relevant neuron-glia interactions and pathways.